Wolverine research monograph — the BPC-157 + TB-500 vendor stack

Wolverine is a vendor-branded peptide stack — named after the Marvel character's
regenerative ability — that combines BPC-157 and TB-500 in a single vial for
tissue-repair research. It is one of the most-asked-about named stacks on the
platform, partly because the underlying pair was already a popular community
combination before any vendor branded it. This monograph lays out what is
actually in a Wolverine vial, what each component contributes mechanistically,
what the literature does and does not show, and what to look for on a COA.

Composition.
Wolverine is a fixed 1:1 BPC-157 : TB-500 blend. Total vial sizes vary across
vendors but the ratio stays constant: TriVial BioWorks sells it as
"Wolverine (BPC-157-10mg/TB-500-10mg)" (20 mg total), Ion Peptide as "Drops –
Wolverine Stack | 20/20mg" (40 mg total), and American Aminos & Peptides
describes their product as a "BPC 157 + TB 500 peptide blend in 5/5mg"
configuration with vial-size options of 10, 20, and 60 mg (5/5, 10/10, and
30/30 mg per component, respectively). Voltera Sciences and Ramp Peptides also
carry the blend in smaller vial sizes following the same 1:1 pattern. The 1:1
ratio is the industry default and is the ratio assumed by every published
community protocol that names "the Wolverine stack."

What each component contributes.
The blend pairs two peptides with complementary tissue-repair profiles.
BPC-157 is a 15-amino-acid synthetic fragment whose preclinical literature
describes effects on angiogenesis (VEGFR2 pathway), nitric-oxide modulation,
gut-mucosal protection, and tendon-fibroblast activity. TB-500 is a synthetic
peptide corresponding to the 17-21 actin-binding region of the larger thymosin
beta-4 protein; rodent studies report effects on cell migration, vascular
remodelling, wound contraction, and reduction of inflammation in injury models.
The rationale for combining them is that BPC-157 is most-characterized for
focal tissue repair (tendon, ligament, gut) while TB-500 is most-characterized
for systemic migration of repair cells to injury sites; the pair has been
hypothesized to act in parallel rather than redundantly.

Research applications.
Wolverine has been used in community and preclinical research settings for
musculoskeletal injury models (tendinopathy, ligament strain, post-surgical
soft-tissue repair), inflammatory bowel research, peripheral nerve injury
models, and chronic-overuse and post-training recovery questions. There is no
published completed human clinical trial of the combined Wolverine blend,
and the published trials of either component individually are essentially
absent — the evidence base for both BPC-157 and TB-500 is dominated by rodent
work from a small number of research groups. Anyone presenting Wolverine as a
proven human therapy is overstating the evidence.

Community protocol information.
Community protocols for Wolverine typically express dosing as a total blend
dose (which, given the 1:1 ratio, also equals the per-component dose). The
most commonly reported research protocol is 250–500 mcg of the blend
administered subcutaneously once or twice daily during the loading phase
(first one to two weeks), then 250 mcg once daily or every other day during
the maintenance phase. Cycle lengths of four to eight weeks "on," followed by
four weeks "off," are the most frequently cited pattern. Some researchers split
the daily dose into a morning and evening administration; others administer
once daily, often timed close to the affected tissue's loading or rehab work.
Routes other than subcutaneous (intramuscular, local-site) appear in animal
literature but are not the default in community protocols. None of these
numbers constitute a clinical recommendation — they are summaries of what the
community reports and should be read alongside the absence of human trial data.

Stack combinations researchers commonly use.
Wolverine is itself a stack, so additional combinations tend to be conservative.
The most commonly reported additions are GHK-Cu (for dermal/scar-remodelling
overlap — this combination is approximately what the GLOW blend already
provides as a fixed formulation), low-dose CJC-1295 + Ipamorelin (for combined
tissue-repair + growth-hormone-axis research questions), and oral collagen
peptides or vitamin C as adjuncts in connective-tissue work. Stacking with NSAID
research models confounds outcomes and is generally avoided in well-designed
protocols.

Storage and handling.
Lyophilized Wolverine vials should be kept refrigerated (2–8 °C) and protected
from light. Once reconstituted with bacteriostatic water, the solution is
typically used within 14–30 days when refrigerated. Both BPC-157 and TB-500
tolerate solution storage reasonably well at refrigerator temperatures, but
neither tolerates repeated freeze-thaw cycles or vigorous shaking. Swirl gently
when reconstituting until clear. The solution is colourless to faintly opaque;
any visible particulate or marked discolouration should be treated as a quality
concern and the batch COA re-checked.

Quality and COA considerations.
A meaningful COA for a Wolverine vial should report identity confirmation for
both peptides (mass spectrometry showing peaks at the expected molecular
weights for BPC-157 and TB-500), purity by HPLC for each component (≥98% is the
practical benchmark), and a fill-weight breakdown that confirms the labelled
1:1 ratio. Single-line "Peptide Blend ≥98%" purity statements without per-
component breakdowns are effectively unverified — they cannot confirm either
the identity or the ratio. Sterility and endotoxin testing should also be
reported if the vial is being used in any model that touches injection or
tissue contact. Sequence-incorrect and underdosed product is a known problem
in this market for both component peptides individually, so a third-party COA
is non-optional for blended products.

*Research-use note: This monograph is an educational summary of the published
research literature and community-reported protocols for the Wolverine
(BPC-157 + TB-500) blend. The combined formulation has not been evaluated in
human clinical trials, and neither component peptide is approved for human use
in any jurisdiction known to VialTalk. Nothing here is medical advice or a
usage recommendation.*